Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
Zwart you may well be right - this is a product that is going to be in demand globally. We have seen it with Covid testing companies where they can literally sell every single unit they manufacturer because the demand is so great. When you are talking about improved patient outcomes then it becomes blindingly obvious where this is going.
In the race to contain CV19 and reduce impact on healthcare systems globally I think we are going to see governments throwing the proverbial kitchen sink at solutions. We should be on standby for emergency approvals of a multitude of therapeutics that have shown positive Phase II clinical trial outcomes (e.g. patient safety has been demonstrated and evidence of therapeutic benefit confirmed). Globally we cannot afford to wait for Phase III trials to conclude so I expect to see some commercialisation of SNG001 much sooner than we might otherwise have expected.
Another acquisition target for NCYT. Imspex have the technology but have neither the finances or market position to make this a reality. We already know the speed at which NCYT can bring new products to market so this could be a good match.
My plan was to take advantage a colleague had the audacity to walk on to my office to talk about work stuff! Next time I looked it was rocketing but still a good enough SP and didn’t stop me getting back on board though!
I sold my latest holding at £9.93 whilst waiting in the queue at the fish and chip ship the other day when the attack on the SP got going - this of course makes me a "panicker" but one who safeguarded a nice profit and for the first time in my dreadful investment history I now find myself able to buy back more shares for less money. Without doubt I am waiting for the opportunity to buy back here as we all know the fundamentals are excellent but I needed to safeguard my profit after some very bitter experiences with other shares this last year.
If true then the current vaccines being developed are not the long term solution unless administered every few months. However, they might provide a bit of a circuit break to coin a current phrase. What this does mean though is that therapeutic approaches are going to be needed for a long time if immunity doesn’t exist.
Positive results from Phase II , current SP, general COVID state of play, lack of immunity, vaccine availability is uncertain, vaccine doubters, vaccine efficacy, potential emergency approval prior to conclusion of phase III.
I sold out of NCYT yesterday, I held on 3 separate occasions making 65%, 25% and 25% profit - nowhere near as some others but better than the bank bound offer me.
I looked here after the placing so now holding and hope you are right that this is the next big one. Looking at the lack of immunity it’s going to take testing and treatment to keep the nation safe so I feel treatment is where the next big rises are going to be found.
This is good news for SNG then as the trial looked at subcutaneous administration and not nebuliser inhalation. The use of a nebuliser ensures the drug is delivered to the target area reducing the first stages of drug metabolism and ensuring higher levels of efficacy.
There are 2 vaccines in the running for administration via a mass vaccination program between December 2020 and August 2021 but likely to be delayed given EMA said approval will be Q1 2021. Mass vaccination program for UK is not using the AZ vaccine.